HIV/AIDS

Stopping Senseless Deaths: Overcoming access barriers to affordable, lifesaving diagnostics and treatments for HIV and opportunistic infections

In 2017, more people than ever – 21.7 million of the world’s 36.9 million HIV-positive people – were receiving antiretroviral treatment (ART). Yet there are persistent – and deadly – gaps in the global response to HIV/AIDS that undermine progress against the epidemic: 25 per cent of people living with HIV do not know their status and only 59 per cent are receiving ART. Millions of people still remain at risk for opportunistic infections (OIs) and death.

This technical brief analyses access barriers to affordable, lifesaving diagnostics and treatments for HIV and OIs, including adult and paediatric formulations of dolutegravir – a highly effective and tolerable HIV integrase inhibitor that replaces efavirenz in first-line treatment regimens. Updated antiretroviral drug pricing information is also provided.

Read more in this briefing document:

Stopping Senseless Deaths - HIV briefing document, July 2018 pdf — 859.91 KB Download
Up Next
Armenia
Project Update 20 December 2018